St. Jude Cardiovascular Access Sales Jump 107% In Q1 To $23 Mil.
This article was originally published in The Gray Sheet
Executive Summary
Strong U.S. sales of the 6 Fr version of St. Jude Medical's Angio-Seal hemostatic puncture closure system since its introduction in mid-March, and "the expansion and focus of cardiology vascular access selling efforts in the U.S.," were the driving forces behind a 107% jump in first quarter cardiovascular access product sales to $23 mil.
You may also be interested in...
Wall Street Apostles Find Salvation In St. Jude During 2Q; Stock Is Up 78%
A continued strong performance by St. Jude Medical's Cardiac Rhythm Management business combined with the expectation of key regulatory approvals by year-end sparked a 77.7% run-up in the company's stock during the second quarter of 2000.
Wall Street Apostles Find Salvation In St. Jude During 2Q; Stock Is Up 78%
A continued strong performance by St. Jude Medical's Cardiac Rhythm Management business combined with the expectation of key regulatory approvals by year-end sparked a 77.7% run-up in the company's stock during the second quarter of 2000.
St. Jude's AVERT Trial Data Induce Recall Of Silzone-Coated Heart Valve
St. Jude Medical's clinical study of the Regent mechanical heart valve henceforth will use only the non Silzone-coated version of the device, following the Jan. 24 recall of all products incorporating the proprietary antimicrobial coating, the firm says.